Longtime Epix Pharmaceuticals chief executive Michael Webb has stepped down from his post, the Cambridge, MA, contrast developer has announced.
Webb is leaving after 11 years at Epix, and will be replaced as interim CEO by Michael Astrue, former president and CEO of Transkaryotic Therapies, also of Cambridge. Astrue will help the company execute its business plan in the imaging field, help define new opportunities outside imaging, and assist the board in its search for a new CEO.
Webb is also resigning his position as a member of the company's board, but will remain as a consultant to the company. The company said that Epix decided on a change in leadership as it is identifying new growth opportunities outside of medical imaging.
By AuntMinnie.com staff writers
September 15, 2005
Related Reading
Epix sales fall, net loss grows, July 28, 2005
Epix makes management moves, July 6, 2005
Epix's Vasovist moves closer to market, July 1, 2005
Epix submits response to FDA, May 23, 2005
Epix revenues, income down in Q1, April 29, 2005
Copyright © 2005 AuntMinnie.com
